GLP-1 Drugs Linked to Lower Death Risk After Diabetic Foot Ulcers
Nationwide French study finds GLP-1 receptor agonist use is associated with significantly reduced 1-year mortality following first diabetic foot ulcer.
Quick Facts
What This Study Found
GLP-1 RA use was associated with reduced 1-year mortality following first diabetic foot ulcer in a nationwide French cohort, with secondary analysis also examining mortality after major lower-limb amputation.
Key Numbers
How They Did This
Retrospective nationwide cohort study using the French SNDS health data system, identifying adults with incident diabetic foot ulcers and analyzing associated factors for 1-year mortality.
Why This Research Matters
Diabetic foot ulcer patients have a 5-year mortality rate approaching 50%. Any treatment that reduces mortality in this population could save thousands of lives annually.
The Bigger Picture
This adds to mounting evidence that GLP-1 drugs reduce mortality across multiple diabetic complications, strengthening the case for earlier and broader use.
What This Study Doesn't Tell Us
Observational design — cannot prove GLP-1 drugs caused the survival benefit. Healthy user bias possible. French healthcare system may not generalize globally.
Questions This Raises
- ?Should GLP-1 drugs be prioritized for diabetes patients with foot ulcer risk?
- ?What mechanism explains the mortality reduction — improved wound healing, cardiovascular protection, or both?
Trust & Context
- Key Stat:
- Reduced 1-year mortality GLP-1 RA users had significantly lower death rates after first diabetic foot ulcer
- Evidence Grade:
- Large nationwide observational cohort — strong real-world evidence but cannot establish causation.
- Study Age:
- Published in 2026; uses comprehensive French national health data.
- Original Title:
- GLP-1 Receptor Agonists Are Associated With Reduced Mortality Following Diabetic Foot Ulcers: A Nationwide Observational Study.
- Published In:
- Diabetes care (2026)
- Database ID:
- RPEP-14893
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs help diabetic foot ulcers?
This large national study found that patients on GLP-1 drugs had significantly lower death rates after diabetic foot ulcers. While the drugs may not directly heal ulcers, they appear to improve overall survival in this high-risk group.
Why are diabetic foot ulcers so dangerous?
Diabetic foot ulcers can lead to serious infections, amputation, and death. Patients with foot ulcers have a 5-year mortality rate approaching 50%, making them one of the highest-risk diabetes populations.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14893APA
Bonnet, Jean-Baptiste; Huguet, Helena; Avignon, Antoine; Duflos, Claire; Sultan, Ariane. (2026). GLP-1 Receptor Agonists Are Associated With Reduced Mortality Following Diabetic Foot Ulcers: A Nationwide Observational Study.. Diabetes care. https://doi.org/10.2337/dc25-2120
MLA
Bonnet, Jean-Baptiste, et al. "GLP-1 Receptor Agonists Are Associated With Reduced Mortality Following Diabetic Foot Ulcers: A Nationwide Observational Study.." Diabetes care, 2026. https://doi.org/10.2337/dc25-2120
RethinkPeptides
RethinkPeptides Research Database. "GLP-1 Receptor Agonists Are Associated With Reduced Mortalit..." RPEP-14893. Retrieved from https://rethinkpeptides.com/research/bonnet-2026-glp1-receptor-agonists-are
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.